Molecular therapeutics from knowledge to delivery

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 6, 2010, Pages 619-623

  Waldman, S A ^a   Terzic, A ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; MERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE; VACCINE; WARFARIN;

ADJUVANT THERAPY; ANTICOAGULANT THERAPY; BIOENGINEERING; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER PATIENT; CANCER PREVENTION; CARCINOGENESIS; CHILDHOOD LEUKEMIA; COLON CANCER; EDITORIAL; GENETIC POLYMORPHISM; HEALTH CARE; HEALTH CARE DELIVERY; HEPATITIS B; HORMONE SUBSTITUTION; KNOWLEDGE; LIVER CELL CARCINOMA; MOLECULAR THERAPY; MORBIDITY; MORTALITY; PALLIATIVE THERAPY; PRIORITY JOURNAL; REGENERATIVE MEDICINE; STEM CELL; TISSUE INJURY; TISSUE REGENERATION; TRANSPLANTATION; UTERINE CERVIX CANCER; VACCINATION; VIRUS INFECTION;

DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG DISCOVERY; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 77952560339     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.61     Document Type: Editorial

References (25)

1. Blaschke, T.F. Global challenges for clinical pharmacology in the developing world. Clin. Pharmacol. Ther. 85, 579-581 (2009).
2. Reynolds, K.S. Drug development for emerging infections. Clin. Pharmacol. Ther. 86, 225-229 (2009).
3. Hotez, P.J. Mass drug administration and integrated control for the world's high-prevalence neglected tropical diseases. Clin. Pharmacol. Ther. 85, 659-664 (2009).
4. Dollery, C.T. Clinical pharmacology in the molecular era. Clin. Pharmacol. Ther. 83, 220-225 (2008).
5. Waldman, S.A. & Terzic, A. Pharmacoeconomics in the era of individualized medicine. Clin. Pharmacol. Ther. 84, 179-182 (2008).
6. Graham, B.S., Ledgerwood, J.E. & Nabel, G.J. Vaccine development in the twenty-first century: changing paradigms for elusive viruses. Clin. Pharmacol. Ther. 86, 234-236 (2009).
7. Fine, B.M. & Amler, L. Predictive biomarkers in the development of oncology drugs: a therapeutic industry perspective. Clin. Pharmacol. Ther. 85, 535-538 (2009).
8. Flockhart, D.A., Skaar, T., Berlin, D.S., Klein, T.E. & Nguyen, A.T. Clinically available pharmacogenomics tests. Clin. Pharmacol. Ther. 86, 109-113 (2009).
9. Ikediobi, O.N. et al. Addressing the challenges of the clinical application of pharmacogenetic testing. Clin. Pharmacol. Ther. 86, 28-31 (2009).
10. Swen, J.J. et al. Pharmacogenetics: from bench to byte. Clin. Pharmacol. Ther. 83, 781-787 (2008).
11. Bartunek, J., Sherman, W., Vanderheyden, M., Fernandez-Aviles, F., Wijns, W. & Terzic, A. Delivery of biologics in cardiovascular regenerative medicine. Clin. Pharmacol. Ther. 85, 548-552 (2009).
12. Nelson, T., Behfar, A. & Terzic, A. Stem cells: biologics for regeneration. Clin. Pharmacol. Ther. 84, 620-623 (2008).
13. Waldman, S.A. & Terzic, A. Therapeutic targeting: a crucible for individualized medicine. Clin. Pharmacol. Ther. 83, 651-654 (2008).
14. Chiang, A.P. & Butte, A.J. Data-driven methods to discover molecular determinants of serious adverse drug events. Clin. Pharmacol. Ther. 85, 259-268 (2009).
15. Deverka, P.A. & McLeod, H.L. Harnessing economic drivers for successful clinical implementation of pharmacogenetic testing. Clin. Pharmacol. Ther. 84, 191-193 (2008).
16. Gomez, A. & Ingelman-Sundberg, M. Pharmacoepigenetics: its role in interindividual differences in drug response. Clin. Pharmacol. Ther. 85, 426-430 (2009).
17. Henderson, J.T. Lazarus's gate: challenges and potential of epigenetic reprogramming of somatic cells. Clin. Pharmacol. Ther. 83, 889-893 (2008).
18. Lathia, C.D. et al. The value, qualification, and regulatory use of surrogate end points in drug development. Clin. Pharmacol. Ther. 86, 32-43 (2009).
19. Lesko, L.J. The critical path of warfarin dosing: finding an optimal dosing strategy using pharmacogenetics. Clin. Pharmacol. Ther. 84, 301-303 (2008).
20. Mager, D.E. & Jusko, W.J. Development of translational pharmacokinetic-pharmacodynamic models. Clin. Pharmacol. Ther. 83, 909-912 (2008).
21. Shields, A.E. & Lerman, C. Anticipating clinical integration of pharmacogenetic treatment strategies for addiction: are primary care physicians ready? Clin. Pharmacol. Ther. 83, 635-639 (2008).
22. Wu, A.C. & Fuhlbrigge, A.L. Economic evaluation of pharmacogenetic tests. Clin. Pharmacol. Ther. 84, 272-274 (2008).
23. Hay, J.W. Using pharmacoeconomics to value pharmacotherapy. Clin. Pharmacol. Ther. 84, 197-200 (2008).
24. Sollano, J.A., Kirsch, J.M., Bala, M.V., Chambers, M.G. & Harpole, L.H. The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace. Clin. Pharmacol. Ther. 84, 263-266 (2008).
25. Romero, K. et al. The Coalition Against Major Diseases: developing tools for an integrated drug development process for Alzheimer's and Parkinson's diseases. Clin. Pharmacol. Ther. 86, 365-367 (2009).